Varian Medical Systems Receives 510(k) Clearance for Fast and Accurate Acuros™ Radiotherapy Treatment Planning Capability

CHARLOTTESVILLE, Va., July 21 /PRNewswire-FirstCall/ -- Varian Medical Systems (NYSE: VAR) today announced that it has received FDA 510(k) clearance for the Acuros™ capability offered initially in its brachytherapy treatment planning system. The Acuros clearance was awarded as part of the market-leading Eclipse™ treatment planning system.

BrachyVision™ Acuros, recently introduced at the American Brachytherapy Society meeting in Toronto, Canada, enables superior dose calculation at unmatched speed. The system enables clinicians to rapidly calculate patient dose with an extremely high level of accuracy*.

"BrachyVision Acuros calculation times tend to average between three and eight minutes depending on the applicator used," says Hosea Mitchell, head of Varian's brachytherapy business unit. "By comparison, the same calculations could take hours or days using the standard Monte Carlo method."

source: Varian Medical Systems